-
Phenytoin for Myelin Remodeling Assays
2026-08-15
Phenytoin provides a practical pharmacological perturbation for testing how sodium-dependent excitability influences myelin swelling, oligodendrocyte survival, and dynamic sheath remodeling. This guide translates recent live-imaging findings into reproducible electrophysiology and neurological disease model workflows, with formulation and troubleshooting guidance.
-
Indomethacin: Practical Research Workflow
2026-08-14
Indomethacin (SKU A8449) provides a defined small-molecule perturbation for cyclooxygenase, PPAR, inflammation, lipid metabolism, and membrane studies. It is suited to controlled mechanistic assays but should not be selected for workflows requiring aqueous formulation or prolonged storage of prepared solutions.
-
Stable Isotope UHPLC–MS/MS for Methylated Purines
2026-08-14
The reference study develops a stable isotope-diluted UHPLC–ESI-MS/MS method for accurately measuring 12 purine ribonucleosides, including 10 methylated species such as 1-methyladenosine. Enhanced ionization, solid-phase extraction, and chromatographic resolution of methylated isomers improve sensitivity in cellular matrices and support future biomarker discovery and RNA modification research.
-
Stabilizing DFCP1–ATGL Lipolysis Experiments
2026-08-13
DFCP1–ATGL biology reveals why extraction quality is part of mechanistic rigor. This thought-leadership guide connects lipid droplet research with practical inhibitor selection, validation controls, and translational strategy using APExBIO’s Protease Inhibitor Cocktail (100X H₂O, EDTA Plus).
-
Protease Inhibitor Cocktail for MS-Safe BMSC Proteomics
2026-08-13
Protect fragile BMSC, migrasome, and signaling proteins during extraction with an AEBSF-free formulation designed for proteomics. This workflow shows how to use broad-spectrum protease inhibition without obscuring CYR61–integrin–ERK biology or compromising mass spectrometry preparation.
-
Protease Inhibitor Cocktail for Plant Extracts
2026-08-12
Protect labile plant proteins during extraction, immunoblotting, co-immunoprecipitation, and kinase workflows with broad-spectrum inhibition and no EDTA carryover. This applied guide translates findings on the NSP2–MYB40 symbiosis module into practical sample-preservation and troubleshooting decisions.
-
Phosphatase Inhibitor Cocktail 2 for Signaling Assays
2026-08-12
Protect phosphorylation-dependent biology from the moment a tissue or cell is lysed with a ready-to-use, broad-spectrum 100X formulation. This workflow-focused guide shows how to apply Phosphatase Inhibitor Cocktail 2 to Western blotting, co-immunoprecipitation, kinase assays, and mechanistic studies of hepatic autophagy.
-
Hybrid Nanovesicles for Klebsiella Pneumonia
2026-08-11
Jiang and colleagues developed hybrid membrane vesicles that combine Klebsiella pneumoniae outer membrane vesicles with alveolar macrophage membranes for single-dose, intratracheal immunization. In mouse models, the platform preserved bacterial immunogenicity while moderating excessive inflammation, reducing tissue bacterial burden, and improving survival after acute pneumonia challenge.
-
Anti-RPS6 Antibody: MA4974 Research Guide
2026-08-11
The Anti-RPS6 antibody MA4974 is an affinity-purified mouse monoclonal reagent for detecting human, mouse, rat, and monkey RPS6 in Western blot, ICC/IF, and immunoprecipitation workflows. It provides a defined research tool for connecting RPS6 measurements with ribosome biogenesis, cell signaling, and cancer-biology studies, while remaining unsuitable for diagnostic or medical use.
-
MAPK10–KRT16 Signaling in NSCLC Metastasis
2026-08-10
The reference study identifies a phosphorylation-dependent MAPK10–KRT16–RNF213 pathway that suppresses non-small cell lung cancer metastasis by promoting KRT16 ubiquitination and proteasomal degradation. Its combination of mechanistic, cellular, animal, and clinical evidence positions this axis as a potential biomarker framework while also highlighting the need for more specific pathway validation.
-
SARS-CoV-2 Nucleocapsid Condensation and GCG
2026-08-09
The reference study identifies RNA-triggered liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic step in viral biology. It further shows that the green-tea polyphenol (-)-gallocatechin gallate disrupts nucleocapsid condensation and suppresses viral replication, establishing condensate regulation as a potential antiviral research direction.
-
tFUS–Nespas–SHP2 Axis in Ischemic Stroke
2026-08-08
A 2025 study links low-intensity transcranial focused ultrasound stimulation (tFUS) with suppression of post-stroke NLRP3 neuroinflammation through the Nespas/miR-383-3p/SHP2 pathway. Using rat ischemic stroke and BV2 microglial models, the work combines behavioral, molecular, transcriptomic, and gene-perturbation evidence to define a mechanistic route for tFUS-mediated neuroprotection.
-
LRPPRC–Dasatinib Synergy in OXPHOS-Dependent Tumors
2026-08-07
The reference study identifies Dasatinib as a synergistic partner for LRPPRC inhibition, using a screen of 1,376 FDA-approved compounds and validation in cancer models. Its central mechanistic insight is that the combination blocks OXPHOS at two levels: LRPPRC inhibition preferentially disrupts mitochondrial genome-encoded components, whereas Dasatinib suppresses nuclear-encoded OXPHOS genes.
-
MRT68921 ULK1 Kinase Inhibitor: Advancing Autophagy Research
2026-08-07
MRT68921 empowers researchers to dissect autophagy signaling with nanomolar precision, offering robust inhibition of ULK1/2 for detailed mechanistic studies. Its selectivity and validated workflows make it indispensable for advanced autophagy inhibition and lipid metabolism research.
-
RIPA Lysis Buffer Strong: Precision Tools for Translational
2026-08-06
Explore how APExBIO’s RIPA Lysis Buffer (Strong, without inhibitors) empowers translational researchers to achieve high-fidelity protein extraction for advanced immunological and biochemical assays. This thought-leadership article integrates mechanistic insights, protocol guidance, and strategic perspectives, bridging preclinical discovery with clinical translation in cancer and immunology.